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Controlling Protein Activity
with Ligand-Regulated RNA Aptamers
environment [13–15]. In addition, ligand binding aptam-
ers inserted into the 5 UTR of messenger RNA allow for
control of gene expression inside living cells [16].
Momchilo Vuyisich and Peter A. Beal1
Department of Chemistry
University of Utah
Salt Lake City, Utah 84112 One potential drawback of the RNA aptamer approach
described above is that once the aptamer is expressed
in the cell and the target protein is inhibited, activity
can no longer be precisely controlled. Tight temporalSummary
regulation of protein activity may be desired in certain
instances when the timing of events is critical, such asControlling the activity of a protein is necessary for
during the cell cycle or in early development [17–19].defining its function in vivo. RNA aptamers are capable
Having an expressed but nonfunctional (inhibited) geneof inhibiting proteins with high affinity and specificity,
product, then activating it at a desired point in timebut this effect is not readily reversible. We describe a
would be valuable in these cases. In such a system, onegeneral method for discovering aptamers that bind
could monitor cellular activities or pathways while theand inhibit their target protein, but addition of a spe-
target protein is inhibited, then activate the protein andcific small molecule disrupts the protein-RNA com-
detect changes.plex. A SELEX protocol was used to raise RNA aptam-
We reasoned that this goal might be accomplisheders to the DNA repair enzyme, formamidopyrimidine
with an RNA aptamer whose binding to the protein wasglycosylase (Fpg), and neomycin was employed in
itself regulated by an organic small molecule. Thus, aeach round to dissociate Fpg-bound RNAs. We identi-
selected RNA could bind and inhibit the target protein.fied an RNA molecule able to completely inhibit Fpg
At a desired point in time, addition of the small moleculeat 100 nM concentration. Importantly, Fpg activity is
(inducer) would disrupt the RNA-protein complex, lead-recovered by the addition of neomycin. We envision
ing to the functional protein (Figure 1). Our approachthese ligand-regulated aptamers (LIRAs) as valuable
was to employ a small molecule in an elution step duringtools in the study of biological phenomena in which
the SELEX protocol, leading to the amplification of RNAsthe timing of molecular events is critical.
that bind a target protein but dissociate from it in the
presence of a small molecule (Figure 2). We refer to
Introduction these RNAs as “ligand-regulated aptamers,” or LIRAs.
In systems that employ LIRAs, a functional protein can
Based on the current data from the human genome be inhibited for a specific period of time as the inhibition
project, the total number of genes is estimated to be is temporally controlled by adding the inducer.
between 35,000 and 45,000 [1]. While functional genet- When considering the desired properties of a ligand-
ics has made great progress in deciphering the roles of regulated inhibitor, we realized that RNA structures
many individual gene products, the process can be slow should be capable of performing such tasks. In addition
and has limitations. In recent years, the field of chemical to aptamers’ ability to bind a variety of proteins, in vitro
genetics has developed new ways of studying protein selected RNAs are capable of recognizing small organic
function by modulating a target protein’s activity with molecules with high affinity and specificity [11, 20, 21].
specific inhibitors [2]. A number of groups have per- Also, there are several examples of ribozymes whose
formed selections from combinatorial libraries and iden- activity can be regulated by the presence of small mole-
tified small molecule inhibitors that target specific pro- cules called effectors [22–25]. These effector-regulated
teins [3–7]. Alternative strategies to the selective ribozymes have been discovered using SELEX, where
inhibition of protein targets have also been developed. a fixed catalytic domain and a known small molecule
In one approach, the active site of the protein is altered binding domain are connected via a randomized RNA
by mutation, and a rationally designed variant of a known “communication module.” Alternatively, the communi-
inhibitor of the wild-type protein is used that is structur- cation module and the catalytic domain can be fixed,
ally complementary only to the mutant [8]. Systematic and the small molecule binding domain can be random-
evolution of ligands by exponential enrichment (SELEX) ized, thus selecting for new effector molecules [26]. In
has also been used to discover RNA molecules (aptam- our approach, all parts of the LIRA are randomized, and
ers) that act as protein inhibitors and exhibit high affinity we simultaneously select for an aptamer that can bind
and specificity for their targets [9–11]. Given that ex- both the protein target and a small molecule.
tremely diverse RNA libraries can be screened and mu- For an initial proof of principle experiment, we chose
tations arising during the selection allow the RNA to both a target protein and a potential inducer that are
evolve the desired properties, this strategy is an attrac- predisposed to bind nucleic acids. For the protein target,
tive one for the discovery of selective protein inhibitors we employed the DNA repair enzyme formamidopyri-
[12]. RNA aptamer inhibitors of proteins have also been midine glycosylase (Fpg), also known as MutM [27, 28].
expressed inside eukaryotic cells and shown to elicit an This enzyme recognizes 8-oxo-dG lesions in DNA and
inhibitory effect on their target proteins in the cellular removes the oxidized nucleotides from the strand, using
its N-glycosylase and AP-lyase activities [29, 30]. Our
choice for the small molecule was neomycin, which be-1Correspondence: beal@chemistry.utah.edu
Chemistry & Biology
908
Figure 3. Progress of the N Selection from Rounds 11–23
The ratio of the RNA amount eluted with wash buffer/neomycin and
RNA eluted with wash buffer alone is plotted as a function of the
round number.
Figure 1. A Schematic Depiction of the Properties of Ligand-Regu-
lated Aptamers
selection, urea continued to be used in the elution step,
A protein of interest is bound and inhibited by a ligand-regulated selecting any RNA structure with affinity for Fpg.aptamer (LIRA). The inhibition is relieved by the addition of a ligand
During the N selection, the progress by round was(inducer) that dissociates the LIRA-protein complex.
measured by calculating the ratio of the amount of RNA
eluted with 5 mM neomycin in the wash buffer and RNA
eluted with wash buffer alone. This ratio climbed to nearlongs to the aminoglycoside class of antibiotics. These
six in round 15 (Figure 3). In round 18, the neomycinmolecules have been shown to bind many naturally oc-
concentration was reduced to 1 mM in order to select forcurring RNA ligands [31–33]. In addition, neomycin was
aptamers more sensitive to neomycin. The ratio droppedused as a SELEX target and shown to bind a specific
but quickly recovered (Figure 3). Finally, 200 M neomy-sequence motif in RNA [34].
cin was used in the last four rounds, after which the
cDNA library was cloned, and the RNAs from this poolResults
were designated N aptamers.
The U selection was performed for a total of 14 rounds,SELEX Results
after which the library was tested for its ability to inhibitRecombinant E. coli formamidopyrimidine glycosylase
Fpg. Under single-turnover conditions, 1M library from(Fpg) enzyme was selected as our initial protein target
the U selection after fourteen rounds completely inhib-[27, 29]. This nucleic acid binding protein is readily over-
ited the enzyme, whereas the same concentration of theexpressed, easily purified, and has a simple, well estab-
initial RNA pool had no effect on Fpg. We cloned thelished assay for activity [28, 35, 36]. A sequence-ran-
cDNA pool at this stage and refer to the RNA clonesdomized RNA library was allowed to bind Fpg in solution
from this selection as U aptamers.followed by separation of free RNA from the Fpg-bound
We tested the ability of the RNA pool from the 23rd Nspecies using filter paper. In the first six rounds, a non-
selection to inhibit Fpg in the presence of neomycin. Asspecific urea buffer was used for elutions of Fpg-bound
a control, we used the RNA pool from the fourteenthRNAs. In round seven, the RNA pool was split and used
round of the U selection. The pool from the N selectionfor two parallel selections. In the N selection, neomycin
was indeed more sensitive to neomycin (by an order ofwas used in the elution step. Therefore, only the RNAs
magnitude) than the U selection pool, which was neverthat bound Fpg but dissociated in the presence of the
pressured to dissociate from Fpg in the presence of theaminoglycoside were collected and amplified. In the U
aminoglycoside. After cloning, we tested 5 N and 9 U
aptamers for their ability to inhibit Fpg with and without
neomycin. In general, N aptamers were more sensitive
to neomycin than U selection aptamers.
Aptamer Binding to Fpg
We tested several aptamers from each selection for their
ability to bind and inhibit Fpg. Based on these results,
we selected two clones (one from each selection) which
bound Fpg with similar affinities and possessed similar
inhibitory activities. We designated these the neomycin-
regulated aptamer (N1) and the control aptamer (U1).
Using a quantitative filter binding assay, the KD was
determined to be 7.5  1.6 nM for N1 and 2.7  0.9 nM
for U1. Our steady-state experiments revealed complete
inhibition of Fpg activity by both N1 and U1 aptamersFigure 2. Selection Strategy for the Discovery of Ligand-Regulated
Aptamers to Proteins at 100 nM concentration.
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Figure 4. Inhibition of Fpg by N1 Aptamer
(A) Fpg activity under steady-state conditions, where S denotes the substrate and P denotes the product band (see Experimental Procedures).
(B) Fpg activity in the presence of 100 nM N1 aptamer. Lanes 2–6 had the following concentrations of neomycin: 1 M, 3 M, 10 M, 30 M,
and 100 M, respectively.
(C) Same reactions as in (B), with U1 aptamer at 100 nM instead of the N1 aptamer.
(D) Same reactions as in (B), with kanamycin instead of neomycin (same concentrations).
(E) Graphical depiction of data from (B)–(D). Data from (B) are represented by squares, from (C) by circles, and from (D) by diamonds.
(F) Structures of two aminoglycosides used in this study, neomycin B and kanamycin A.
Effects of Neomycin on Aptamer Inhibition of Fpg dicted secondary structure of the aptamer (Figure 5B).
The mapping also includes the major cleavage sites ofWe wished to determine the relative response of the
two selected aptamers to the presence of neomycin. T1 ribonuclease digest under native conditions, which
are shown in Figure 6A, lane 4. In general, the reactivityReaction components (aptamer, Fpg, and an aminogly-
coside antibiotic) were incubated together, followed by observed with the different ribonucleases agrees with
the predicted secondary structure.the addition of labeled Fpg substrate under steady-state
conditions. Full inhibition of the Fpg activity is observed
with the N1 aptamer present at 100 nM concentration Footprinting of Fpg and Neomycin
(Figure 4B, lane 1). As increasing concentrations of neo- on the Neomycin-Regulated Aptamer
mycin are added, the aptamer inhibition of Fpg is re- In order to locate the binding sites for Fpg and neomycin
lieved (Figure 4B, lanes 2–6). At 100 M neomycin, the on the N1 aptamer, cleavage protection assays (foot-
Fpg activity approaches its maximum, in which 2 nM printing) were performed. We utilized several ribo-
product is observed (compare lanes 0 and 6). The neo- nucleases (S1, V1, T1, and P1) for this purpose, and the
mycin rescue was not observed when the control ap- results can be best demonstrated by ribonuclease T1
tamer (U1), which binds Fpg with similar affinity as N1, footprinting (Figure 6). Figure 6A shows that cleavage
was used to inhibit the enzyme (Figure 4C). To determine by T1 diminishes at G27 as neomycin is added (lanes
if the disruption of the N1-Fpg complex is specific to 5–13). Lanes 14–19 show a decrease in T1 cleavage
neomycin, we repeated the experiment with the structur- from G27 to G35 in response to increasing amounts of
ally similar aminoglycoside kanamycin (Figure 4F). Im- Fpg. Thus, Fpg and neomycin bind the N1 aptamer at
portantly, this related aminoglycoside is unable to inter- apparently overlapping sites at the junction between a
fere with the inhibitory activity of the N1 aptamer under stem structure and a single-stranded loop near the cen-
these conditions (Figure 4D). The amount of product ter of the RNA strand (Figure 6B). When protection from
(nM) in Figures 4B–4D was quantified and plotted as a T1 cleavage is converted to fraction RNA bound by neo-
function of aminoglycoside concentration (Figure 4E). mycin, the data can be fitted using a single-site binding
equation, which results in a Kd of 0.94  0.06 M (Fig-
ure 6C).Secondary Structure of the Neomycin-
Regulated Aptamer
Sequencing of cDNA for the N1 aptamer allowed us The Importance of the 3 Stem-Loop
of N1 Aptamerto predict the RNA’s secondary structure using the
computer program MFOLD (http://bioinfo.math.rpi.edu/ From the predicted secondary structure and the location
of Fpg and neomycin binding sites on N1 aptamer, themfold/rna/form1.cgi) (Figure 5B) [37]. To test the pre-
dicted model, we used ribonucleases specific for single- 3 stem-loop of the RNA (nucleotides 60–91) appeared
to be dispensable. To test this idea, we prepared twoand double-stranded RNA, which included S1, V1, and
T1. Figure 5A shows cleavage of N1 aptamer by S1 deletion mutants of the N1 aptamer, comprising 59 or
66 nucleotides from the 5 end. Neither of these RNAsand V1 ribonucleases under native conditions. Major
cleavage sites on the RNA are mapped onto the pre- was able to inhibit Fpg at 200 nM concentration. This
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Figure 5. N1 Aptamer Secondary Structure
Prediction and Structure Probing
(A) Ten percent polyacrylamide gel showing
cleavage of N1 by single-strand (S1) and dou-
ble-strand (V1) specific ribonucleases. Lane
1, alkaline hydrolysis; lane 2, G lane (RNase
T1); lane 3, RNA only; lane 4, RNA  0.1 mM
ZnCl2; lane 5, RNA 2 u/L S1; lane 6, RNA
5 u/L S1; lane 7, RNA  10 u/L S1; lane 8,
RNA  1 u/mL V1; lane 9, RNA  2 u/mL V1;
lane 10, RNA  10 u/mL V1.
(B) Secondary structure of N1 aptamer pre-
dicted by MFOLD. Major cleavage sites of S1,
V1, and T1 ribonucleases are represented by
circles, triangles, and arrows, respectively.
The major cleavage sites identified for ribo-
nucleases S1 and V1 are those observed in
lanes 6 and 9, respectively.
result indicates that the 3 stem-loop is important for complement existing functional genetics approaches
[2–8, 12]. One of these methods relies on the selectionthe inhibitory effect of N1, perhaps in maintaining the
aptamer’s three-dimensional structure. of an RNA aptamer inhibitor of the protein, which is
then expressed inside the target cell [12]. These RNA
molecules are able to specifically block the function ofDiscussion
a gene product. In this work, we build on this idea and
present a method for temporally controlling the activitySeveral chemical genetics methods have been devel-
oped to delineate the functions of gene products that of a gene product which involves an RNA aptamer as
Figure 6. Fpg and Neomycin Footprints on N1 Aptamer
(A) Ten percent polyacrylamide gel showing T1 RNase cleavage of N1 in the presence of Fpg and neomycin. Lane 1, alkaline hydrolysis; lane
2, G lane (RNase T1); lane 3, RNA only; lanes 4–19, 1 u/mL T1 RNase; lanes 5–13, increasing concentrations of neomycin as follows: 0.03 M,
0.1 M, 0.3 M, 1 M, 3 M, 10 M, 30 M, 100 M, 300 M; lanes 14–19, increasing concentrations of Fpg as follows: 0.3 nM, 1 nM, 3 nM,
10 nM, 30 nM, 100 nM.
(B) N1 secondary structure with brackets showing Fpg and neomycin binding sites.
(C) Fraction N1 bound by neomycin is plotted as a function of the aminoglycoside concentration.
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the inhibitor of the target protein and a small molecule we believe this proof of principle exercise will pave the
way for applications involving proteins whose roles arecapable of relieving that inhibition (the inducer).
We utilized the SELEX method to evolve RNA aptam- poorly understood and small molecules that are cell
permeable and nontoxic. In the example reported here,ers that bind the DNA repair protein formamidopyrimi-
dine glycosylase, Fpg [11]. In addition, we introduced a we chose to use the presence of a small molecule as the
switch in protein activity. In principle, other conditionsstep in the selection where RNA was eluted from filter-
bound protein using the aminoglycoside antibiotic neo- could also have been chosen. For instance, an aptamer
that dissociates from the target protein in the presencemycin. This was the critical step that allowed us to col-
lect and amplify only the RNA structures that satisfied or absence of a specific metal ion or by a change in pH
could lead to other means by which the target proteintwo criteria: (1) the RNA must bind Fpg, and (2) the
Fpg-bound RNA must dissociate from the protein in the could be regulated [39]. This could lead to a method to
regulate protein activity only in certain cellular compart-presence of neomycin. After 23 rounds of SELEX and
initial characterization of five clones, we further investi- ments or only in cells responding to a specific environ-
mental stimulus.gated the properties of clone N1, a 91-mer RNA aptamer.
To ensure that the features of the N1 RNA were not In addition to these chemical genetic applications,
the discovery of new protein-RNA complexes that arearrived at by chance, we also performed a selection with
Fpg using a highly stringent, nonspecific elution buffer disrupted by small molecules will lead to a better under-
standing of the inhibition mechanisms possible. Indeed,(see Experimental Procedures). One of the clones from
this selection (designated U1) bound Fpg with an affinity as more LIRA/protein/small molecule combinations are
discovered and structurally, kinetically, and thermody-similar to that of N1 and was used for comparison to N1.
Although both N1 and U1 aptamers bind and inhibit namically characterized, an opportunity will exist to
identify features of the protein-RNA complexes thatFpg similarly, the two aptamers showed dramatically
different inhibitory activities in the presence of neomycin make them susceptible to regulation by small molecules.
This information will be valuable to those designing(Figure 4). While most of the Fpg activity was rescued
from inhibition by N1 in the presence of 100 M neomy- small molecule inhibitors of naturally occurring and
functionally important protein-RNA complexes [40].cin, the same concentration of the aminoglycoside had
only a minimal effect on Fpg inhibition by the U1 ap-
tamer. Furthermore, no appreciable rescue of Fpg activ-
Significanceity was observed with 100 M kanamycin, an aminogly-
coside structurally related to neomycin. Thus, the ability
Several chemical genetics techniques have been de-of neomycin to rescue Fpg activity from the inhibitory
veloped that complement functional genetics in deci-effect of the N1 aptamer is dependent both on the struc-
phering the cellular function of gene products [2–8,ture of the evolved RNA aptamer and the small molecule
12]. One of these approaches utilizes RNA aptamersused during the selection.
that inhibit their target proteins in vivo [12, 15]. We haveTo shed light on the mechanism by which neomycin
extended the utility of this approach by demonstratingregulates the N1 aptamer, we carried out secondary
that RNA inhibitors of protein function can be discov-structure prediction, structure probing studies, and foot-
ered through in vitro evolution and are released fromprinting with this RNA. These experiments suggested a
their targets in the presence of specific small mole-probable secondary structure as well as identified bind-
cules (inducers). This allows for greater temporal con-ing sites for Fpg and neomycin on the RNA. It is apparent
trol of the targeted protein activity, as it can be reacti-that the selection carried out led to the isolation of an
vated upon addition of the inducer at a specific timeaptamer that had overlapping binding sites for Fpg and
point. This method should prove particularly usefulneomycin, suggesting the mode of action of neomycin
in defining the function of gene products involved inis a competitive one (Figure 6). Interestingly, the se-
phenomena where the timing of events is critical, suchquence at the neomycin binding site is similar to those
as the cell cycle, circadian clocks, or embryonic devel-previously implicated in binding aminoglycosides. For
opment. In addition, in-depth studies of ligand-regu-example, the 5-GU-3 step, which is present in N1 ap-
lated aptamers like those described here will identifytamer as G27 and U28, has recently been shown to
features of protein-RNA complexes that make thembind the aminoglycoside deoxystreptamine ring [32]. In
susceptible to regulation by small molecules.addition, neomycin binding aptamers contain G-rich re-
gions adjacent to a bulge, which is similar to the 5 end
Experimental Proceduresof N1 aptamer [34].
The method developed here for discovering a LIRA/
General
small molecule pair is potentially general for any target Distilled, deionized water was used for all aqueous reactions and
protein or protein domain. Such inhibitor/inducer pairs dilutions. Biochemical reagents were obtained from Sigma/Aldrich
could be used to inhibit proteins in vivo, then relieve unless otherwise noted. Restriction enzymes and nucleic acid modi-
fying enzymes were purchased from New England Biolabs. Oligonu-the inhibition at desired points in time. This would be
cleotides were prepared on a Perkin Elmer/ABI Model 392 DNA/RNAvaluable for the study of cellular phenomena in which
synthesizer with -cyanoethyl phosphoramidites. 5-Dimethoxytritylthe timing of molecular events is critical, such as in
protected 2-deoxyadenosine, 2-deoxyguanosine, 2-deoxycytidine,cell cycle regulation, circadian clocks, or controlling cell
and thymidine phosphoramidites were purchased from Perkin El-
fates during early development. A system that includes mer/ABI. [-32P]ATP (6000 Ci/mmol) and [32P]pCp (3000 Ci/mmol)
neomycin as the inducer is probably not suitable for a were obtained from DuPont NEN. Storage phosphor autoradiogra-
phy was carried out using imaging plates purchased from Kodak.cell biology application due to its toxicity [38]. However,
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A Molecular Dynamics STORM 840 was used to obtain all data from and visualized using phosphorimager screens. The amount of prod-
uct was calculated as a percent of 20 nM substrate and without anyphosphorimaging plates.
inhibitors was measured to be approximately 2 nM under these
conditions.Fpg Purification
E. coli Fpg was overexpressed and purified as previously described
[28, 35, 36]. We estimated that the enzyme was 70% active. Secondary Structure Prediction and Testing
Secondary structure prediction was performed using the web-based
MFOLD program on Dr. Michael Zuker’s website, http://bioinfo.Random Library Preparation
math.rpi.edu/mfold/rna/form1.cgi [37]. Testing of the predictedA 105 nt DNA oligonucleotide (0.2 nmol) was used as the template
structure was carried out using T1, S1, and V1 ribonuclease digests.for a three-cycle PCR reaction, which yielded a 130 bp dsDNA
All reactions were carried out for 10 min at room temperature in 1product consisting of a T7 promoter and a 60-mer random region
SB under native conditions and in the presence of 10g/mL of yeastflanked by EcoRI and HindIII cloning sites. Transcription from this
tRNAPhe. In the case of S1 ribonuclease, reactions were supplied withDNA generated a 105-nt-long random RNA pool [41].
0.1 mM ZnCl2 for optimal activity.
Selections
T1 Quantitative FootprintingIn each round, 2 nmol of RNA pool was denatured at 95C in 0.5
Footprints for both Fpg and neomycin were obtained using T1ml of the selection buffer (1 SB: 10 mM Tris-HCl, 50 mM NaCl, 2.5
RNase under native conditions. The reactions were performed inmM MgCl2 [pH 7.0]) and allowed to slowly cool to room temperature.
1 SB at room temperature with 10 g/mL of tRNAPhe. IncreasingA single 13 mm filter paper disc (HAWP01300, Millipore) was added
amounts of Fpg or neomycin were incubated with 10 nM labeledto the RNA pool, and the tube was gently mixed for 20 min. This
aptamer for 10 min, followed by a 10 min enzyme digest. The reac-step excluded filter paper binding RNAs. The RNA pool was then
tions were quenched with 15 l of stop solution, heat denatured,transferred to a tube with 0.3 nmol of Fpg and allowed to bind for
and 5 l of each was resolved on 10% denaturing PAGE. After20 min with gentle mixing. To separate Fpg-bound from free RNA,
phosphorimaging the gel, the cleavage efficiency at G27 was calcu-a vacuum manifold-mounted 96-well plate with filter paper bottoms
lated by subtracting the background band in the control lane and(MAVM096OR and MAHAS4510, Millipore) was used. The binding
normalizing for the different loading per lane. The cleavage datareaction was loaded into a well, and vacuum was applied for 1 min.
were converted into binding data for neomycin, assuming that theUnbound RNAs passed through the filter, while Fpg and the bound
maximum cleavage corresponds to 0% occupancy by neomycinRNAs were retained. The RNA-protein complexes were washed with
and that the minimum cleavage corresponds to 100% occupancy1 ml of 1 SB to remove weakly binding RNAs. In the first six rounds,
by neomycin. Fraction of aptamer bound by neomycin was plottedthe Fpg-bound RNAs were eluted with 0.2 ml of urea elution buffer
as a function of neomycin concentration, and the data were fitted(100 mM Na citrate, 7 M urea, 10 mM EDTA [pH 5.2]) which was
using a single-site binding equation: fraction bound 	 [neo] /preheated to 65C. The eluted RNAs were washed three times with
([neo]  Kd). The results are reported as the average and standard0.5 ml water in a YM-10 microcon concentrator (Millipore), then
deviation for three different experiments.treated with 5 units of RNase-free DNase I (Promega) for 3 hr at
37C . Access RT-PCR kit (Promega) was used to amplify RNA
winners from each round. After six rounds, the RNA pool was divided Acknowledgments
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